0001493152-26-023862
SEC filingSCN-102 launch drove 449% revenue growth to $56.3K amid post-divestiture streamlining, narrowing operating losses 1.7% to -$3.5M, though net losses widened 11% to -$3.4M due to R&D and fees, with cash at $3.5M signaling funding needs.
Revenue grew 449.1% year-over-year to $56.3K in Q1 FY2026 from $10.3K, fueled by the launch of SCN-102 (Arbli™) into wholesale distribution channels post-FDA approval. This topline acceleration reflects early commercialization traction in a market favoring reduced dosing volume and room-temperature stable formulations, marking Scienture's shift toward CNS/CVS-focused products after divesting legacy subsidiaries in April 2025.
Net income reflected a wider -$3.4M loss, 11.0% deeper than prior year's -$3.1M, pressured by increased R&D investments in dominant pipeline programs like SCN-106 and higher professional fees. Diluted EPS improved 75.8% to -$0.08 from -$0.33, highlighting per-share loss reduction amid these dynamics. Net cash provided by operating activities showed a slight improvement to -$2.9M from -$3.0M, with the modest decrease driven by working capital changes partially offset by elevated operating expenses during the period.